⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PBM News
Psyence Biomedical Ltd. Common Shares
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
globenewswire.com
PBM
From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape
globenewswire.com
FOLD
PBM
PRPH
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
globenewswire.com
PBM
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
globenewswire.com
PBM
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
globenewswire.com
PBM
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
globenewswire.com
PBM
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
globenewswire.com
PBM
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
globenewswire.com
PBM
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
globenewswire.com
PBM